

# The Decay of the Chromosomally Encoded *ccd*<sub>O157</sub> Toxin–Antitoxin System in the *Escherichia coli* Species

Natacha Mine, Julien Guglielmini, Myriam Wilbaux and Laurence Van Melderen<sup>1</sup>

Laboratoire de Génétique et Physiologie Bactérienne, Institut de Biologie et Médecine Moléculaires, Faculté des Sciences, Université Libre de Bruxelles, 6041 Gosselies, Belgium

Manuscript received August 18, 2008  
Accepted for publication January 27, 2009

## ABSTRACT

The origin and the evolution of toxin–antitoxin (TA) systems remain to be uncovered. TA systems are abundant in bacterial chromosomes and are thought to be part of the flexible genome that originates from horizontal gene transfer. To gain insight into TA system evolution, we analyzed the distribution of the chromosomally encoded *ccd*<sub>O157</sub> system in 395 natural isolates of *Escherichia coli*. It was discovered in the *E. coli* O157:H7 strain in which it constitutes a genomic islet between two core genes (*folA* and *apaH*). Our study revealed that the *folA*–*apaH* intergenic region is plastic and subject to insertion of foreign DNA. It could be composed (i) of a repetitive extragenic palindromic (REP) sequence, (ii) of the *ccd*<sub>O157</sub> system or subtle variants of it, (iii) of a large DNA piece that contained a *ccd*<sub>O157</sub> antitoxin remnant in association with ORFs of unknown function, or (iv) of a variant of it containing an insertion sequence in the *ccd*<sub>O157</sub> remnant. Sequence analysis and functional tests of the *ccd*<sub>O157</sub> variants revealed that 69% of the variants were composed of an active toxin and antitoxin, 29% were composed of an active antitoxin and an inactive toxin, and in 2% of the cases both ORFs were inactive. Molecular evolution analysis showed that *ccd*<sub>O157</sub> is under neutral evolution, suggesting that this system is devoid of any biological role in the *E. coli* species.

**B**ACTERIAL chromosomes and plasmids harbor, often in multiple copies, addiction modules also known as toxin–antitoxin (TA) systems (for a review, see GERDES *et al.* 2005). They generally consist of two genes: a toxin-encoding gene whose product affects the bacterial metabolism (replication or translation) and an antitoxin-encoding gene whose product binds to the toxin and counteracts its activity. The antitoxin is constantly degraded by an ATP-dependent protease while the toxin is a stable protein. This property renders the cell addicted to antitoxin production and therefore to the TA genes. This has been well documented for plasmid-encoded TA systems. Their biological role is to help maintain plasmids in growing bacterial populations by killing plasmid-free daughter bacteria (addiction phenomenon or postsegregational killing, PSK) (GERDES *et al.* 1986; YARMOLINSKY 1995). The function(s) of chromosomally encoded TA systems, however, still remains unclear. While it was proposed that chromosomally encoded *mazEF* and *relBE* systems of *Escherichia coli* K-12 are stress response modules, it was recently shown that the five canonical TA systems of *E. coli* K-12 (including *relBE* and *mazEF*) do not confer any selective advantage under a variety of stress conditions (CHRISTENSEN *et al.* 2003; KOLODKIN-GAL and ENGELBERG-KULKA 2006; TSILIBARIS *et al.* 2007).

This raises the distinct possibility that chromosomally encoded TA systems might be devoid of function, at least in the global stress response. Nevertheless, recent studies have highlighted a variety of physiological processes involving chromosomally encoded TA systems such as developmental programming (NARIYA and INOUE 2008), persistence (KEREN *et al.* 2004), stabilization of large genomic fragments (SZEKERES *et al.* 2007), and anti-addiction (SAAVEDRA DE BAST *et al.* 2008). Thus, the functions of chromosomally encoded TA systems are likely to be quite diverse, depending on the type of TA systems, their genomic location (plasmid, genomic island, chromosomal core), and their host species.

Seven families of TA systems have been defined on the basis of the homology of the toxin proteins (PANDEY and GERDES 2005). One of the striking features of these systems is their wide distribution in bacterial and archeal genomes. Most of the genomes that have been sequenced do contain TA systems (PANDEY and GERDES 2005; SEVIN and BARLOY-HUBLER 2007) although to various extents. Some of the TA families are highly prevalent (such as *relBE* and *vapBC*) while others appear to be less represented (*phd-doc* and *ccd*) (PANDEY and GERDES 2005). The *ccd* family is mostly confined to  $\gamma$ -proteobacteria and only a small number of chromosomally encoded homologs have been identified and studied so far (WILBAUX *et al.* 2007; SAAVEDRA DE BAST *et al.* 2008).

A chromosomally encoded homolog of the *ccd*<sub>F</sub> system of the *E. coli* F plasmid was previously character-

<sup>1</sup>Corresponding author: Laboratoire de Génétique et Physiologie Bactérienne, Institut de Biologie et Médecine Moléculaires, Faculté des Sciences, Université Libre de Bruxelles, 12 rue des Professeurs Jeener et Brachet, B:6041 Gosselies, Belgium. E-mail: lvmelder@ulb.ac.be

ized in *E. coli* O157:H7 EDL933 and found to be expressed and still functional (WILBAUX *et al.* 2007). Indeed, the ectopic expression of this CcdB<sub>O157</sub> toxin is lethal through gyrase poisoning, while the coexpression of the CcdA<sub>O157</sub> antitoxin relieves its toxicity. The *ccdO157* system is located between the *folA* and *apaH* metabolic genes, coding, respectively, for a dihydrofolate reductase and a diadenosine tetraphosphatase. Bioinformatics analysis on *E. coli* genomic sequences available at the time (17 partial or complete sequences) indicated a certain degree of plasticity in this region (WILBAUX *et al.* 2007). In the present work, we have analyzed the *folA*–*apaH* intergenic region of a collection of 395 *E. coli* isolates representing the 174 known serogroups. The aim of this study is to evaluate the prevalence of the chromosomally encoded *ccdO157* system within *E. coli* species and to gain insight into the evolution of TA systems.

## MATERIALS AND METHODS

**Bacterial strains:** *E. coli* strains used in this work, their origin, and their pathogenic or commensal nature are listed in supplemental Table S1. Three hundred ninety-five *E. coli* strains were obtained from various sources. Sixty-nine strains were obtained from academic hospitals (48 from the Hôpital Universitaire des Enfants Malades Reine Fabiola, Université Libre de Bruxelles, Belgium and 21 from the Academisch Ziekenhuis, Vrije Universiteit Brussel, Belgium). Three hundred six strains were obtained from collections [2 from the Collection de l'Institut Pasteur, (Paris), 130 from the Shiga Toxin-Producing *Escherichia coli* Center (Michigan State University), and 174 from Laboratorio de Referencia de *E. coli* (Universidad de Santiago de Compostela, Spain)]. Eighteen strains were obtained from stools from healthy volunteers and 2 from urine of patients with a diagnosed cystitis. Identification of these 20 strains was confirmed using the VITEK 2 (BioMérieux, Marcy l'Etoile, France). All the strains, besides those received from LREC, were serogrouped using the complete serogrouping kit from LREC. *E. coli* serogrouping relies on the nature of the O antigen. One hundred seventy-four different serogroups have been described.

In addition, the MG1655 (wild-type *E. coli* K-12) (GENTRY *et al.* 1991) and the SG22622 (MC4100 *cpsB::lacZ ara malP::lacF*) (from S. Gottesman) laboratory strains were used.

**Media:** Luria–Bertani medium (LB) (MILLER 1972), Ceria 132 synthetic medium (CM), (GLANSDORFF 1965), and CM supplemented with 0.1% casamino acids (CCM) were used.

**DNA manipulations:** Transformations with appropriate plasmids were performed as described in MILLER (1972), and most routine DNA manipulations were performed as described in SAMBROOK and RUSSELL (2001).

**PCR detection of the *ccdO157* system:** Presence of the *ccdO157* system was examined in all our *E. coli* isolates by PCR, using primers flanking the *folA*–*apaH* intergenic region: primer 40-bis (5'-GCAGAACTCTCAGCTATT-3') complementary to the 3'-end of the *folA* gene and primer 93 (5'-TTGTCCAGCCGTCGAACCGGC-3') complementary to the 3'-end of the *apaH* gene (Figure 1). The strains presenting a PCR amplicon of 151 bp (which corresponds to a *folA*–*apaH* intergenic region of 77 bp) were further screened by PCR with primers complementary to the *ccdO157* system of EDL933 to possibly detect it at different locations. For this purpose, primer 43 (5'-TTGTTCTAGAAATTGTACAGGAGCAGC-3') complementary




FIGURE 1.—PCR detection of the *ccdO157* system in the *E. coli* species. The *ccdO157* system is located between the *folA* and the *apaH* gene (not on scale). Its presence was detected by PCR using the P40 and P93 primers that are complementary to the ORFs that are flanking the *ccdO157* system. Another set of primers (P43 and P47) complementary to the *ccdA<sub>O157</sub>* and *ccdB<sub>O157</sub>* ORFs was used to detect it at other potential chromosomal locations in strains that did not carry *ccdO157* between *folA* and *apaH*.

to the 5'-end of the *ccdA<sub>O157</sub>* gene and primer 47 (5'-AGTCTCTGCAGTTAAATCCCGTCCGAGC-3') complementary to the 5'-end of the *ccdB<sub>O157</sub>* gene were used. As an internal control, primers 16SA (5'-CCCCCTGGACGAAGACTGAC-3') and 16SB (5'-ACCGCTGGCAACAAAGGATA-3') complementary to 16S rRNA were used in PCR reactions.

**Sequencing of the *folA*–*apaH* intergenic region:** To ensure a diverse sampling of the *E. coli* population, the *folA*–*apaH* intergenic region of 93 isolates was sequenced using primers 40-bis and 93 (see supplemental Table S1, in boldface type). The sequence of the 712-bp fragment obtained in 47 different serogroups, as well as that of the 1499-bp fragment in 20 different serogroups, and that of the unique 2778-bp fragment was analyzed. The 151-bp fragment was analyzed for the 25 serogroups that presented a high variability in PCR size. In the case of the 712-bp fragments, the DNA sequence was translated and compared to the CcdA<sub>O157</sub> and CcdB<sub>O157</sub> protein sequences from the *E. coli* O157:H7 EDL933 reference strain using BLASTP. For the 1499- and 2778-bp fragments, the ORFs were determined using ORFinder.

**Construction of the *ccdA* and *ccdB* expression plasmids:**  
*pBAD33-derivative plasmids:* The variants of the chromosomally encoded *ccdB<sub>O157</sub>* gene were amplified from a boiled colony from the various serotypes using the primers 5'-CcdBO157-*Xba*I (5'-GCTCTAGAAGGAGGTAGCGATGCAATTACGG-3') and 3'-CcdBO157-*Pst*II (5'-AGTCGCTGCAGCTAGAAGCTCCGGTAC-3'). The variants of the F-plasmid-encoded *ccdB<sub>F</sub>* gene were amplified using OLI 70 (5'-TCTAGAAGGAGGTGAAATGCA GTTTAAGG-3') and OLI 71 (5'-AGTCGCTGCAGTTATATT CCCAGAAC-3'). The 5'-primers (CcdBO157-*Xba*I and OLI 70) carried a canonical Shine–Dalgarno (SD) sequence (in boldface type). The PCR products were digested with *Xba*I and *Pst*II (in italics) and ligated downstream of the P<sub>BAD</sub> promoter of the pBAD33 vector cut with the same restriction enzymes. The recombinant plasmids were sequenced. The different variants were named according to the serotype of the strain.

*pKK223-3-derivative plasmids:* The variants of the chromosomally encoded *ccdA<sub>O157</sub>* gene were amplified on a boiled colony from the various serotypes using the primers 5'-CcdAO157-*Eco*RI (5'-TTGTGAATTCTATGACTGCAAAACGTACC A-3') and 3'-CcdAO157-*Pst*II (5'-AGTCTCTGCAGCTAGAAG CTCCGGTACTC-3'). The variants of the plasmid-encoded *ccdA<sub>F</sub>* gene were amplified using P502 (5'-TTGTGAATTCTAT GAAGCAGCGTATTACAGTGACAG-3') with P516 (5'-AGTCTCTGCAGTCCAGTC CCTGTTCTC-3'). The PCR products were cloned into the TOPO-XL vector (Invitrogen, Carlsbad, CA) and sequenced. The recombinant TOPO-XL plasmids were then digested with *Eco*RI and *Pst*II (in italics) and the corresponding DNA fragments were ligated downstream of the *lac*/*trc* promoter in the pKK223-3 vector opened with the same restriction enzymes. The recombinant plasmids were

sequenced. The different variants were named according to the serotype of the strain.

**Toxicity and antitoxicity plate assays:** To test the toxicity of the cloned CcdB<sub>O157</sub> and CcdB<sub>F</sub> variants, the corresponding pBAD33-*ccdB* constructs were transformed in MG1655. The resulting transformants were plated on LB plates containing chloramphenicol with or without arabinose (1%). The CcdB variants were considered to be functional (toxic) when transformants were able to grow only in the absence of arabinose.

To test the ability of the cloned CcdA<sub>O157</sub> and CcdA<sub>F</sub> variants to counteract the toxicity of CcdB<sub>O157</sub> and CcdB<sub>F</sub>, respectively, the corresponding pKK-*ccdA* constructs were transformed in MG1655 expressing the reference *ccdB*<sub>O157</sub> or *ccdB*<sub>F</sub> genes from the pBAD33 vector. The resulting transformants were plated on LB plates containing chloramphenicol and ampicillin with arabinose (1%). Basal expression of *ccdA* from the pTac promoter of pKK223-3 in MG1655 is sufficient to test the antitoxicity phenotype. The CcdA variants were considered to be functional when the toxicity of CcdB<sub>O157</sub> or CcdB<sub>F</sub> protein was counteracted, *i.e.*, when strains coexpressing a *ccdA* variant with the *ccdB*<sub>O157</sub> or *ccdB*<sub>F</sub> reference genes were able to grow in the presence of arabinose while strains expressing only the *ccdB*<sub>O157</sub> or *ccdB*<sub>F</sub> reference gene were not.

**Toxicity and antitoxicity liquid assays:** Strains carrying the toxin-expressing plasmids and/or the antitoxin-expressing plasmids were grown overnight (ON) at 37° in CCM supplemented with glucose (0.4%) and the appropriate antibiotics. ON cultures were diluted in the same medium to an optical density (OD) at 600 nm of 0.01 and grown at 37° to an OD<sub>600</sub> of 0.1–0.2. The cultures were centrifuged at 4000 rpm for 10 min at room temperature. The bacterial pellets were resuspended in CCM, prewarmed at 37°, and supplemented with glycerol (0.4%) and the appropriate antibiotics. Arabinose was then added (0.25 or 1%), and the cultures were grown at 37°. Samples were removed at the indicated time, diluted in MgSO<sub>4</sub> (10 mM), and plated on CCM plates supplemented with glucose (0.4%) and the appropriate antibiotics.

**Construction of the O51 Δ*ccd*<sub>O51</sub> strain:** The pKOBEG plasmid (CHAVEROCHE *et al.* 2000) was transformed to *E. coli* O51 and used as described at the website <http://www.pasteur.fr/recherche/unites/Ggb/3SPCRprotocol.html>. The kanamycin resistance cassette of pKD4 was amplified by PCR with the following primers: P1 (5'-ATACTAGACGTATAAATTGTACAGGAGCAGATATCGTGTAGGCTGGAGCTGCTTC-3') and P6 (5'-AAAGATATGGGTGAGGGAGAGGCGGCCGCGTCTTAA CATATGAATATCCTCCTTAG-3'). Deletion of the *ccd*<sub>O51</sub> system was constructed by following the method described in reference DATSENKO and WANNER (2000). The deletion and the flanking regions were checked afterward by DNA sequencing.

**Simpson index:** To measure the diversity of the CcdB<sub>O157</sub> and CcdA<sub>O157</sub> sequences, the Simpson index was calculated as

$$\sum_{i=0}^n p_i^2,$$

with  $n$  being the total number of different variants of each gene and  $p$  their frequencies. The value of the Simpson index is between 0 (maximum diversity) and 1 (no diversity, one variant) (SIMPSON 1949).

**Natural selection measurements:** To evaluate the nature and magnitude of natural selection acting on the *ccdB*<sub>O157</sub>, *folA*, and *apaH* genes, the  $d_N/d_S$  ratio ( $\omega$ ) was calculated. We were unable to carry such an analysis for *ccdA*<sub>O157</sub> due to the small number of variants. For the 14 variants of the chromosomally encoded CcdB<sub>O157</sub> found in this study, an amino acid-based nucleotide alignment of the variants was built, along with 13 CcdB<sub>F</sub> plasmid-encoded homologs, using the online version of MAFFT v6 (KATOY *et al.* 2002; KATOY and TOH 2008). The

following plasmids were considered: the pIP1206, pSE11, pETEC-74, pETEC-80, and pO113 *E. coli* plasmids; the pBS 512-211 and pCP301 Shigella plasmids; and the pCVM29188, pCVM291882, pOU1115, pOU7519, and pOU1113 from various Salmonella isolates. The *folA* and *apaH* genes from the 47 serogroups (isolates from which the *ccd*<sub>O157</sub> system was sequenced. The *FolA*FOR (5'-GCACCAGTCGACGACGGTTTAC-3') and P47 primers and *ApaREV* (5'-CTTTCAGCATCGACATTCCCG-3') and P43 primers were used for *folA* and *apaH*, respectively. The *apaH* sequence was complete (846 bp) while we analyzed ~86% of the sequence of *folA* [from base pair 58 to the end (420 bp)].

The *folA* and *apaH* alignments were made manually. Twenty-four and 38 variants were identified for *folA* and *apaH*, respectively.

Phylogenetic analyses were carried out with the maximum-likelihood method as implemented in the online version of Bootstrap RAXML (STAMATAKIS *et al.* 2008) available on the CIPRES portal ([http://www.phylo.org/sub\\_sections/portal/](http://www.phylo.org/sub_sections/portal/)). Since we wanted to compare  $\omega$  for plasmid and chromosomally encoded *ccdB* sequences, we used PAML v4.1 (YANG 1997, 2007) with the branch model. This model assumes nonindependent ratios for each branch, the user being allowed to specify which branches should have which rates. We fixed one rate ( $\omega_1$ ) for the plasmid sequences, another ( $\omega_2$ ) for the chromosome ones, and a last ( $\omega_0$ ) for all the internal branches. The *folA* and *apaH* ratios were calculated using the same model, with for each analysis one rate ( $\omega_1$ ) for the sequences and one rate ( $\omega_0$ ) for all the internal branches. To obtain the variance on the  $d_N/d_S$  values, we computed the pairwise  $\omega$ -ratios for each couple of sequences using DNA Master (<http://cobamide2.bio.pitt.edu/computer.htm>). These ratios were weighted according to the inverse of the distance between the two sequences. The weighted pairwise  $\omega$  allowed us to calculate the variance on the  $d_N/d_S$  ratios.

## RESULTS

**Size variability of the *folA*–*apaH* intergenic region within the *E. coli* species:** In *E. coli* O157:H7 EDL933, the *ccd*<sub>O157</sub> system is located between the *folA* and the *apaH* genes (WILBAUX *et al.* 2007). To evaluate the general prevalence of this system in *E. coli* species, PCR was used to probe the *folA* and *apaH* intergenic region (IR) of 395 *E. coli* isolates. Interestingly, four different lengths of PCR amplicons were obtained: (i) a fragment of 151 bp, which corresponds to the *folA*–*apaH* intergenic region in MG1655 K-12; (ii) a fragment of 712 bp, which corresponds to the *ccd*<sub>O157</sub> system in the O157:H7 EDL933 strain; (iii) a fragment of 1499 bp; and (iv) a fragment of 2778 bp (Figure 2). The actual sizes of the IR are shown in Table 1. The isolates presenting the 151-bp fragment were further screened by PCR with primers specific to the *ccd*<sub>O157</sub> system and not the *ccd*<sub>F</sub> system (primers 43 and 47, see MATERIALS AND METHODS). No amplification was obtained, suggesting that these isolates did not carry the *ccd*<sub>O157</sub> system at another chromosomal location and/or on a plasmid.

Our collection is composed of the 174 different *E. coli* serogroups that have been described so far. Although most of them are represented by only one isolate, 54 different serogroups contained at least 2 independent




FIGURE 2.—Diversity of the *folA-apaH* region in the *E. coli* species. PCR reactions were carried out on *E. coli* isolates using P40 and P93. Lane 1, molecular weight marker (SMART ladder, Eurogentec), size is indicated in base pairs; lane 2, MG1655; lane 3, O157 (2886-75, STEC Center); lane 4, O153 (LREC); lane 5, O163 (LREC); lane 6, O86 (LREC); lane 7, negative control. The size (base pairs) of the different amplicons is indicated.




FIGURE 3.—Diversity of the *folA-apaH* region within the O153 serogroup. PCR reactions were carried out on three O153 isolates using P40 and P93. Lane 1, molecular weight marker (SMART ladder, Eurogentec), size is indicated in base pairs; lane 2, negative control; lane 3, HC45; lane 4, MG1655; lane 5, HC71; lane 6, O153 (LREC). The size (base pairs) of the different amplicons is indicated.

isolates. Table 1 shows the variability of the *folA-apaH*IR among the 174 serogroups. The 151-bp fragment was detected in isolates belonging to 135 different serogroups, while the 712-bp fragment was present in 47 different serogroups. The 1499-bp fragment was less prevalent and was detected in 20 different serogroups, while the 2778-bp fragment was detected in only one serogroup (O163). This shows that independent isolates from the same serogroup may display a different IR (29 over 174 serogroups). For instance, 14 serogroups contained isolates presenting a fragment of 151 or 712 bp, while 19 contained only isolates presenting the 151-bp fragment and 9 only those at 712 bp (data not shown). Moreover, the variability of the *folA-apaH* IR region among one serogroup was very high for some serogroups and low for others, and this variability was not correlated to the number of isolates per serogroup. Serogroups such as O153 and O23 contained isolates presenting the 151-, 712-, and 1499-bp PCR fragments (see Figure 3 for O153) and the O111 serogroup contained 18 isolates presenting the 1499-bp fragment and 14 presenting the 151-bp fragment (Table 2). Other sero-

TABLE 1

Diversity of the *folA-apaH* intergenic region among 395 *E. coli* isolates belonging to 174 serogroups

Size (bp)		No. of serogroups	No. of isolates	No. of fragments sequenced
PCR	IR	( <i>n</i> = 174)	( <i>n</i> = 395)	( <i>n</i> = 93)
151	77	135	196	25
712	638	47	137	47
1499	1425	20	61	20
2778	2704	1	1	1

The PCR amplicon (PCR) and actual intergenic region (IR) sizes are indicated.

groups display no variability among the different isolates (Table 2). For instance, the 19 isolates of serogroup O55 all harbored the 712-bp fragment.

All together, these results show that the *folA-apaH*IR is highly diversified and is most likely a region that allows integration of foreign DNA. No correlation between the presence of a *ccd*<sub>O157</sub> system and the strain serogroup could be highlighted.

**The plasticity of the *folA-apaH* intergenic region:** As shown in Table 1, 135 serogroups contained isolates showing a *folA-apaH* IR of 77 bp, 47 serogroups contained the 638-bp *ccd*<sub>O157</sub> system (see below), 20 serogroups contained isolates displaying an IR of 1425 bp, and one isolate had an IR of 2704 bp. Figure 4A shows the IRs of various sizes and their content. The 77-bp IR was sequenced for 25 serogroups and was found to be identical to that of the MG1655 strain. This IR is composed of a repetitive extragenic palindromic (REP) sequence (WILBAUX *et al.* 2007). The 1425-bp fragments were sequenced for 20 isolates and were highly similar. We identified a small sequence that presents identity with the 3' region of *ccdA*<sub>O157</sub> and two putative ORFs (Figure 4, A and B). The sequenced *E. coli* B7A, *E. coli* E110019, and *E. coli* SMS-3-5 strains also present the 1425-bp IR. ORF2 presents identity with hypothetical proteins from other bacterial species, *i.e.*, *E. albertii* TW07627 and *Bacteroides uniformis* ATCC 8492. ORF3 shows identities with a large number of hypothetical proteins found in bacteria, fungi, and amoebas and one in a sea urchin. The 2704-bp IR corresponds to that of 1425 bp with the insertion of an IS62I in the sequence presenting identity with *ccdA*<sub>O157</sub> (nt 83).

**Variants of the *ccd*<sub>O157</sub> system:** Table 1 shows that 137 isolates, spread over 47 serogroups, display a *folA-apaH* IR of 638 bp, indicating the presence of the *ccd*<sub>O157</sub> system within the IR. Of each serogroup, the IR of one

**TABLE 2**  
Diversity of the *folA*–*apaH* intergenic region among isolates belonging to the same serogroups

Serogroup	Total no. of isolates	No. of isolates with an IR of 151 bp	No. of isolates with an IR of 712 bp	No. of isolates with an IR of 1499 bp
O2	10	—	10	—
O26	19	—	—	19
O55	19	—	19	—
O111	32	14	—	18
O128	15	10	—	5
O157	24	1	23	—

Serogroups represented by at least 10 isolates are indicated.

such isolate was sequenced (in boldface type in supplemental Table S1) and found indeed to correspond to the *ccd*<sub>O157</sub> system or subtle variants of it. Table 3 shows the amino acid sequences of the corresponding CcdA and CcdB proteins. The 47 antitoxin proteins presented very few variations, except in the case of CcdA<sub>O138</sub>. Overall, seven classes of alleles could be identified. The most prevalent one was identical to the *ccdA*<sub>O157</sub> gene of the O157:H7 EDL933 reference strain (37/47 isolates). Five classes, representing 9/47 isolates, presented single point variations (S76R, A54T, D72E, T47I, or T34M). The capacity of 1 representative protein of each class to antagonize the toxic activity of the reference CcdB<sub>O157</sub> protein was tested, using the antitoxicity plate assay (see MATERIALS AND METHODS). The single point variations did not affect the capacity of the CcdA variants to antagonize CcdB<sub>O157</sub> activity (data not shown, Table 3). The last class (1 isolate) presented a frameshift

mutation caused by a 1-nt deletion. This led to a major modification of the carboxy terminus of CcdA<sub>O138</sub> that affects the antitoxic activity of this variant. Indeed, when coexpressed with CcdB<sub>O157</sub>, this protein was unable to restore viability, showing that CcdA<sub>O138</sub> is inactive (Figure 5A). This result was expected since it has been shown that the carboxy-terminal domain of CcdA<sub>F</sub> is responsible for the antitoxin activity (BERNARD and COUTURIER 1991).

Interestingly, the CcdB toxin proteins were much more diversified than the antitoxins. Among the 47 serogroups, 14 classes of alleles could be identified. Note that, as mentioned earlier, only one isolate for each serogroup was sequenced and tested (47 isolates). One class was composed of 4 isolates presenting sequence identical to the *ccdB*<sub>O157</sub> gene of the O157:H7 EDL933 reference strain. The 2 most prevalent classes represented 13/47 and 8/47 isolates, and the corresponding




FIGURE 4.—Plasticity of the *folA*–*apaH* IR within the *E. coli* species. (A) Representation of the diversity of the *folA*–*apaH* IR. The strains and the size (base pairs) of the different *folA*–*apaH* intergenic regions (IR) are indicated. The *folA* and *apaH* genes are represented in black. The *ccdA*<sub>O157</sub> and *ccdB*<sub>O157</sub> genes are represented in white and dark gray, respectively (indicated as A and B). A' represents the 3'-terminal part of the *ccdA*<sub>O157</sub> gene. ORF2 (129 amino acids) is represented in light gray, ORF3 (199 amino acids) in white, and IS621 in stippled white. (B) Sequence alignment of the seq1 sequence and CcdA<sub>O157</sub>. The amino acid sequences were aligned with CLUSTALW. Symbols: asterisk, identical amino acids; colon, strongly similar amino acids; period, weakly similar amino acids. The total number of amino acids for each protein is in parentheses.

TABLE 3  
The variants of CcdA<sub>O157</sub> and CcdB<sub>O157</sub> proteins

Strain serogroup	No. of isolates	Antitoxin activity	CcdA variants	Amino acid sequence
157 (EDL933 reference strain)	—	+	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF SDEYRSF-----77	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF SDEYRSF-----77
2/4/5/6/11/15/16/17/22/ 23/24/25/33/45/51/52/ 55/58/81/83/85/86/89/ 112/114/115/120/134/ 139/142/145/150/153/ 157/161/166/176 44/133	37	+	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77
1/7/75/79	4	+	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77
171	1	+	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF SEYRSF-----77	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF SEYRSF-----77
119	1	+	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77
102	1	+	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77	MTAKRITQSVITVDRELVNRARDAGLNMSATLTVLNAELKKHAATRWEENAEIAAALNQLADETGCF DEYRSF-----77
138	1	—	MTAKRITQSVITVDRELVNRARDAGLNMSAPLRLRSMLNKNMQQHVGVKRTQKLSLR-----59	MTAKRITQSVITVDRELVNRARDAGLNMSAPLRLRSMLNKNMQQHVGVKRTQKLSLR-----59
Strain serogroup	No. of isolates	Toxic activity	CcdB variants	Amino acid sequence
157 (EDL933 reference strain)	—	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
44/55/157/171	4	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
24/33/52/112/114/145/ 176/115	8	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
11/58/161	3	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
133	1	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
85/89	2	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
2/45/83	3	—	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104
81	1	+	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104	MQFTVYRSRNRNAAFPFVIDVTSDIIGVINRRRIVIPLTPIERFSRIRPPERLNPILLVLDGKEYVLMTHETATVPV NALGTFKFCDSAHRTLLKCALDFMLDGI-----104

(continued)

**TABLE 3**  
(Continued)

Strain serogroup	No. of isolates	Toxic activity	Amino acid sequence
1/4/5/6/16/22/25/75/79/120/134/142/150	13	+	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRRIVIPLTPIERFSRIRPERLNPIILLVVDGKEYVLMTHETATVPV NALGTFKCDASAHRIILKCALDFMLDGI-----
102	1	NT	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRRIVIPLTPIERFSRIRPERLNPIILLVVDGKEYVLMTHETATVPV NALGTFK-----
138/153	2	-	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRRIVIPLTPIERFSRIRPERLNPIILLVVDGKEYVLMTHETATVPV NALGTFKCDASAHRIILKCALDFMLDGI-----
166	1	-	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRRIVIPLTPIERFSRIRPERLNPIILLVVDGKEYVLMTHETATVPV NALGTFK-----
17/15	2	-	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRSIVPLTPIERFSRIRPERLNPIILLVVDG-----
23/51/86/119/139	5	-	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRRIVIPLTPIERFSRIRPERLNPIILLVVDG-----
7	1	NT	MQFTVYRSRGRNAAFPFVIDVTSDIIGEINRRIVIPLTPIE-----

NT, not tested; +, active for either toxicity or antitoxicity; -, not active for either toxicity or antitoxicity. Amino acid variation as compared to amino acid sequence of the reference *CcdA*<sub>O157</sub> and *CcdB*<sub>O157</sub> proteins is indicated in italics. The *CcdA* and *CcdB* variants that have been tested experimentally are represented in boldface type.

alleles harbored either two variations (S10G and V28E) or one variation (S44I), respectively. The toxic activity of at least one representative *CcdB* protein of each class was tested using the toxicity plate assay (see MATERIALS AND METHODS) and was comparable to that of the *CcdB*<sub>O157</sub> protein. Four classes, together representing 7 isolates (7/47), contained from one to five variations (V28E, RH7-V28E, S10G-I26V-V28E, and RH7-S10G-I26V-V28E-I93L). At least one representative of each class was assayed for toxicity using the toxicity plate assay. Interestingly, expression of these variants led to cell killing, showing that the variations did not affect the toxic activity of the *CcdB* proteins. Of the 7 classes remaining, 1 is composed of 2 isolates (representing serogroups O138 and O153) containing four variations in their *ccdB* gene (S10G-V28E-S44I-P54T). The *CcdB*<sub>O138</sub> protein (from serogroup O138) was assayed for toxicity and surprisingly shown not to affect viability upon ectopic expression (Figure 5B). The comparison of the variations among the different classes suggests that the P54T mutation is responsible for abolishing the toxic activity of the *CcdB*<sub>O138</sub> variant. The 6 last classes, representing 13/47 isolates, were composed of truncated proteins. Deletions of the carboxy-terminal region were caused by amber mutations at various locations (E41, R42, E63, and C84). Interestingly, all these truncated proteins contained several point variations that were also found in the full-length variants that were still toxic (S10G, I26V, V28E, and S44I) or not (R7H and P54T). Two of these classes (7/47 isolates) contained one extra variation (K62S), while another class (1/47 isolates) contained two more variations (R11S and R32S). One representative of 4 of these 6 classes was tested and was shown to be nontoxic, using the plate toxicity assay (data not shown). Figure 5B shows that ectopic overexpression of *CcdB*<sub>O51</sub> in the liquid toxicity assay did not lead to the loss of viability. These truncated variants of *CcdB*<sub>O157</sub> are thus inactive and it is likely to be the case for *CcdB*<sub>O7</sub> and *CcdB*<sub>O102</sub> since the active site of the *CcdB*<sub>O157</sub> is located at the carboxy terminus of the protein (BAHASSI *et al.* 1995; WILBAUX *et al.* 2007). The corresponding antitoxins were functional (Table 3).

These results showed that while the vast majority of the *ccd*<sub>O157</sub> system or variants of it were composed of an active antitoxin (46/47), the proportion of active toxins was much smaller (31/45 tested). Thus, 69% of the variants (31/45) were composed of an active toxin and antitoxin, 29% (13/45) were composed of an active antitoxin and an inactive toxin, and in 2% (1/45) of the cases both ORFs are inactive. The Simpson index measurements showed that the antitoxin sequences are homogeneous (0.63) while the toxin sequences show a high level of diversity (0.14).

**Evolution of the *ccd*<sub>O157</sub> system and its flanking regions:** To evaluate the nature of the selective pressures acting on the *ccd*<sub>O157</sub> system, the *d<sub>N</sub>/d<sub>S</sub>* ratio for the *CcdB*<sub>O157</sub> proteins was measured and compared to that




FIGURE 5.—Properties of the *ccd*<sub>051</sub> and *ccd*<sub>0138</sub> variants. (A) The CcdA<sub>0138</sub> protein is not able to counteract the toxicity of CcdB<sub>0157</sub>. SG22622/pKK223-3/pBAD33-*ccd*B<sub>0157</sub> (triangle), SG22622/pKK-*ccd*A<sub>0138</sub>/pBAD33-*ccd*B<sub>0157</sub> (square), and SG22622/pKK-*ccd*A<sub>0157</sub>/pBAD33-*ccd*B<sub>0157</sub> (diamond) were grown in the presence of 1% arabinose. (B) The CcdB<sub>051</sub> and CcdB<sub>0138</sub> variants are not toxic. SG22622/pBAD33 (diamond), SG22622/pBAD33-*ccd*B<sub>051</sub> (square), SG22622/pBAD33-*ccd*B<sub>0138</sub> (circle) and SG22622/pBAD33-*ccd*B<sub>0157</sub> (triangle) were grown in the presence of 1% arabinose. In A and B serial dilutions of the cultures were plated at regular time intervals on CCM plates without arabinose and incubated overnight at 37°. Values correspond to the mean of results of three independent experiments and SDs are indicated. (C) The CcdA<sub>051</sub> protein is expressed in *E. coli* O51 and counteracts the toxicity of CcdB<sub>0157</sub> expressed in *trans*. O51 (triangle) and O51Δ*ccd*<sub>051</sub> (square) containing the pBAD33 vector (solid symbols) or the pBAD33-*ccd*B<sub>0157</sub> plasmid (open symbols) were grown in the presence of 0.25% arabinose. At regular time intervals, serial dilutions of the cultures were plated on CCM plates without arabinose and incubated overnight at 37°. Values correspond to the mean of results of three independent experiments and SDs are indicated.

of 13 CcdB<sub>F</sub> homologs found on plasmids (see MATERIALS AND METHODS). The  $d_N/d_S$  for the plasmid-encoded toxin proteins reflected a negative selection ( $0.11 \pm 0.0035$ ), showing that these sequences are very constrained. On the contrary, the  $d_N/d_S$  value for the chromosomally encoded toxins was close to 1 ( $0.9 \pm 0.1665$ ), indicating a neutral selection. This analysis could not be performed for *ccd*A<sub>0157</sub> due to the small number of variants, indicating that the antitoxin sequences are highly constrained. The evolution of the *folA* and *apaH* genes flanking the *ccd*<sub>0157</sub> system appeared to be also constrained ( $0.03 \pm 0.0004$  and  $0.32 \pm 0.0166$ , respectively).

**Expression of the *ccd*<sub>051</sub> system in *E. coli* O51:** A quite significant proportion of systems (29%) are constituted of an inactive toxin and an active antitoxin. To better characterize this type of variant, the expression of such a system was analyzed. For that purpose, we deleted the *ccd*<sub>051</sub> system in *E. coli* O51. Strains O51 and O51Δ*ccd*<sub>051</sub> were transformed with the pBAD-*ccd*B<sub>0157</sub> plasmid. The viability of both strains was measured upon expression of the CcdB<sub>0157</sub> toxin. Figure 5C shows that the viability of the O51Δ*ccd*<sub>051</sub> strain was more strongly affected than that of the O51 strain by ectopic overexpression of CcdB<sub>0157</sub>. This shows that CcdA<sub>051</sub> is still induced from its natural location at a basal level that is sufficient to at least partially counteract the toxic activity of CcdB<sub>0157</sub> produced in *trans*.

## DISCUSSION

Our work revealed that the intergenic region between the *folA* and *apaH* genes is a hot spot for integration of exogenous mobile genetic elements. In several *E. coli* isolates that have been fully sequenced, this region is composed of a REP sequence (WILBAUX *et al.* 2007). REP sequences are noncoding, short (21–65 nt) palindromic sequences detected in bacterial chromosomes in multiple copies in intergenic regions and between genes from the same operon (GILSON *et al.* 1984; STERN *et al.* 1984). REPs have been shown to be the integration site for various insertion sequences (CLEMENT *et al.* 1999; CHOI *et al.* 2003; WILDE *et al.* 2003; TOBES and PAREJA 2006). Among the 395 *E. coli* isolates that were tested in this work, (i) 49.6% (196/395) had the REP sequence in the *folA*–*apaH* IR; (ii) 34.7% (137/395) had the *ccd*<sub>0157</sub> system or variants of it; (iii) 15.4% (61/395) contained two hypothetical ORFs, one of them being largely represented even in eukaryotic cells, and a 3' remnant of the *ccd*A<sub>0157</sub> gene; and (iv) 0.3% (1/395) contained an IS621 inserted in this remnant sequence. No sign of REP-like sequence or inverted repeat was detected in the *ccd*A<sub>0157</sub> remnant. How the *ccd*<sub>0157</sub> system was inserted at that location remains also unclear since no transposase gene or repeats are detectable (WILBAUX *et al.* 2007). We can hypothesize that it originated from a larger composite



transposon that was trimmed with evolution. Unfortunately, we were unable to retrace the evolutionary history of that region and to determine whether one or several insertion/deletion events have occurred. However, comparing the sequences of the *ccd*<sub>O157</sub> system and its variants did provide insights about its evolution. Thirty percent of the variants of the chromosomally encoded *ccd*<sub>O157</sub> system are composed of an inactive toxin. A similar survey, although less extensive, was carried out for the *ccd*<sub>F</sub> plasmid-encoded system within the same isolate collection (data not shown). The variants of the CcdB<sub>F</sub> toxin that were sequenced and tested were toxic, indicating that the plasmid-encoded systems are under a stronger selective pressure to retain their addiction function. This was confirmed by molecular evolutionary analysis of the CcdB<sub>F</sub>-like toxins encoded by various plasmids.

It is likely not to be the case for the chromosomal ones since a significant proportion of the toxin variants were inactive. The  $d_N/d_S$  ratio showed that the CcdB<sub>O157</sub>-like toxins were under neutral selection, suggesting that this system might be devoid of any biological role. Interestingly, the evolution of *ccdA*<sub>O157</sub>-like antitoxins and of the flanking *apaH* and *folA* genes appears to be much more constrained. Inactivation of the toxin gene prior to the antitoxin gene presumably constitutes the first and safer step of TA systems degradation. Moreover, at least in the case of *E. coli* O51, the regulatory regions remain unchanged since this strain was resistant to a moderate expression of the CcdB<sub>O157</sub> toxin in *trans*. The case of *ccd*<sub>O138</sub> reinforces the hypothesis that toxin inactivation arises first. Indeed, the inactive CcdB<sub>O138</sub> variant is coupled either to the inactive CcdA<sub>O138</sub> as in the case of the *ccd*<sub>O138</sub> variant or to an active antitoxin as in the case of the *ccd*<sub>O153</sub> variant. Thus, the situation at present strongly indicates a decay of the *ccd*<sub>O157</sub> system. An alternative hypothesis is that the antitoxin might play an anti-addictive role as shown for the *ccd*<sub>Ech</sub> system (SAAVEDRA DE BAST *et al.* 2008) although not against CcdB<sub>F</sub>-like toxin since CcdA<sub>O157</sub> antitoxin does not protect against *ccd*<sub>F</sub> addiction (WILBAUX *et al.* 2007). Therefore, we are in favor of a degeneration of the chromosomally encoded *ccd*<sub>O157</sub> system.

The role of chromosomally encoded TA systems remains controversial. The well-studied *mazEF* and *relBE* systems of *E. coli* K-12 were reported to be induced under stress conditions (*e.g.*, amino acid starvation, antibiotic treatments, and heat shock) although the outcome of their induction is quite different and controversial: induction of *mazEF* was shown to lead to programmed cell death, while that of *relBE* induces a bacteriostatic state (GERDES *et al.* 2005; ENGELBERG-KULKA *et al.* 2006). Moreover, in competition experiments between the wild-type strain and a strain devoid of 5 TA systems (among them *mazEF* and *relBE*) under stress conditions, no selective advantage of the wild-type strain was evident (TSILIBARIS *et al.* 2007), further underscoring the discrepancy with the stress response model. Our present

observations add to this and indicate that the chromosomally encoded *ccd*<sub>O157</sub> system might actually be devoid of any biological role in the *E. coli* species although the *ccd*<sub>O157</sub> variants are composed in 69% of the cases of active ORFs (a toxin that when ectopically overexpressed inhibits colony formation and an antitoxin that relieves the toxin toxicity).

A still striking and not yet understood observation is the abundance of TA systems in bacterial chromosomes (PANDEY and GERDES 2005; SEVIN and BARLOY-HUBLER 2007; GUGLIELMINI *et al.* 2008). Although no extensive comparative bioinformatics analysis has been carried out, there is indication that TA systems are part of genomic islands (PANDEY and GERDES 2005; MAGNUSON 2007). As for the *ccd*<sub>O157</sub> system, they might constitute an "islet" by themselves. This indicates that they disseminate and invade chromosomes through horizontal gene transfer. We propose that some TA systems might be maintained in bacterial chromosomes without conferring any selective advantage to the host, but only due to the interdependence of the toxin and antitoxin ORFs (selfish view). In time, genetic drift might lead to the appearance of inactive toxin mutants, which could then be selected for if sporadic toxin induction proves disadvantageous for the cell. Unless chromosomally encoded TA systems become accommodated in regulatory networks, such as developmental programming (NARIYA and INOUE 2008) and persistence (KEREN *et al.* 2004), TA systems would gradually degenerate and eventually disappear.

While the bioinformatics approach constitutes a powerful tool for detecting TA systems, we should consider the possibility that some of them might be pseudogenes. An integrated approach of bioinformatics and experimental characterization will certainly provide valuable information about the evolution of TA systems.

We thank Régis Hallez, Abram Aertsen, and Manuel Saavedra De Bast for their comments on the manuscript. We are grateful to Régis Hallez and Damien Geeraerts for their assistance in cloning toxin and antitoxin genes and Michel Milinkovitch for providing advice for molecular evolution analysis. We thank Denis Piérard (Academisch Ziekenhuis Vrije Universiteit Brussel, Brussels), Anne Vergison (Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Belgium), and Beth Whittam (STEC Center, Michigan State University) for providing us with the *E. coli* strains and Jean-Marc Ghigo and Christophe Beloin (Institut Pasteur, Paris) for the pKOBEG plasmid. This work was supported by the European Union (Combating Resistance to Antibiotics; Specific Targeted Research Project, LSH-2004-2.1.2-2), by the Fonds de la Recherche Scientifique Médicale (3.4510.02), and by the Fonds Brachet. At the time of this work, M.W. was supported by the Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture and the European Union (CRAB STREP LSH-2004-2.1.2-2).

#### LITERATURE CITED

- BAHASSI, E. M., M. A. SALMON, L. VAN MELDEREN, P. BERNARD and M. COUTURIER, 1995 F plasmid CcdB killer protein: *ccdB* gene mutants coding for non-cytotoxic proteins which retain their regulatory functions. *Mol. Microbiol.* **15**: 1031–1037.
- BERNARD, P., and M. COUTURIER, 1991 The 41 carboxy-terminal residues of the miniF plasmid CcdA protein are sufficient to antagonize the killer activity of the CcdB protein. *Mol. Gen. Genet.* **226**: 297–304.

- CHAVEROCHE, M. K., J. M. GHIGO and C. D'ENFERT, 2000 A rapid method for efficient gene replacement in the filamentous fungus *Aspergillus nidulans*. *Nucleic Acids Res.* **28**: E97.
- CHOI, S., S. OHTA and E. OHTSUBO, 2003 A novel IS element, IS621, of the IS110/IS492 family transposes to a specific site in repetitive extragenic palindromic sequences in *Escherichia coli*. *J. Bacteriol.* **185**: 4891–4900.
- CHRISTENSEN, S. K., K. PEDERSEN, F. G. HANSEN and K. GERDES, 2003 Toxin-antitoxin loci as stress-response-elements: ChpAK/MazF and ChpBK cleave translated RNAs and are counteracted by tmRNA. *J. Mol. Biol.* **332**: 809–819.
- CLEMENT, J. M., C. WILDE, S. BACHELLIER, P. LAMBERT and M. HOFNUNG, 1999 IS1397 is active for transposition into the chromosome of *Escherichia coli* K-12 and inserts specifically into palindromic units of bacterial interspersed mosaic elements. *J. Bacteriol.* **181**: 6929–6936.
- DATSENKO, K. A., and B. L. WANNER, 2000 One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. USA* **97**: 6640–6645.
- ENGELBERG-KULKA, H., S. AMITAI, I. KOLODKIN-GAL and R. HAZAN, 2006 Bacterial programmed cell death and multicellular behavior in bacteria. *PLoS Genet.* **2**: e135.
- GENTRY, D., H. XIAO, R. BURGESS and M. CASHEL, 1991 The omega subunit of *Escherichia coli* K-12 RNA polymerase is not required for stringent RNA control in vivo. *J. Bacteriol.* **173**: 3901–3903.
- GERDES, K., P. B. RASMUSSEN and S. MOLIN, 1986 Unique type of plasmid maintenance function: postsegregational killing of plasmid-free cells. *Proc. Natl. Acad. Sci. USA* **83**: 3116–3120.
- GERDES, K., S. K. CHRISTENSEN and A. LOBNER-OLESEN, 2005 Prokaryotic toxin-antitoxin stress response loci. *Nat. Rev. Microbiol.* **3**: 371–382.
- GILSON, E., J. M. CLEMENT, D. BRUTLAG and M. HOFNUNG, 1984 A family of dispersed repetitive extragenic palindromic DNA sequences in *E. coli*. *EMBO J.* **3**: 1417–1421.
- GLANSORFF, N., 1965 Topography of cotransducible arginine mutations in *Escherichia coli* K-12. *Genetics* **51**: 167–179.
- GUGLIELMINI, J., C. SZPIRER and M. C. MILINKOVITCH, 2008 Automated discovery and phylogenetic analysis of new toxin-antitoxin systems. *BMC Microbiol.* **8**: 104.
- KATO, K., and H. TOH, 2008 Recent developments in the MAFFT multiple sequence alignment program. *Brief. Bioinform.* **9**: 286–298.
- KATO, K., K. MISAWA, K. KUMA and T. MIYATA, 2002 MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* **30**: 3059–3066.
- KEREN, I., D. SHAH, A. SPOERING, N. KALDALU and K. LEWIS, 2004 Specialized persister cells and the mechanism of multi-drug tolerance in *Escherichia coli*. *J. Bacteriol.* **186**: 8172–8180.
- KOLODKIN-GAL, I., and H. ENGELBERG-KULKA, 2006 Induction of *Escherichia coli* chromosomal *mazEF* by stressful conditions causes an irreversible loss of viability. *J. Bacteriol.* **188**: 3420–3423.
- MAGNUSON, R. D., 2007 Hypothetical functions of toxin-antitoxin systems. *J. Bacteriol.* **189**: 6089–6092.
- MILLER, J., 1972 *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- NARIYA, H., and M. INOUE, 2008 MazF, an mRNA interferase, mediates programmed cell death during multicellular *Myxococcus* development. *Cell* **132**: 55–66.
- PANDEY, D. P., and K. GERDES, 2005 Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. *Nucleic Acids Res.* **33**: 966–976.
- SAAVEDRA DE BAST, M., N. MINE and L. VAN MELDEREN, 2008 Chromosomal toxin-antitoxin systems may act as antiaddiction modules. *J. Bacteriol.* **190**: 4603–4609.
- SAMBROOK, J., and D. RUSSELL, 2001 *Molecular Cloning: A Laboratory Manual*, Ed. 3. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- SEVIN, E. W., and F. BARLOY-HUBLER, 2007 RASTA-Bacteria: a web-based tool for identifying toxin-antitoxin loci in prokaryotes. *Genome Biol.* **8**: R155.
- SIMPSON, E. H., 1949 Measurement of diversity. *Nature* **163**: 688.
- STAMATAKIS, A., P. HOOVER and J. ROUGEMONT, 2008 A rapid bootstrap algorithm for the RAxML web servers. *Syst. Biol.* **57**: 758–771.
- STERN, M. J., G. F. AMES, N. H. SMITH, E. C. ROBINSON and C. F. HIGGINS, 1984 Repetitive extragenic palindromic sequences: a major component of the bacterial genome. *Cell* **37**: 1015–1026.
- SZEKERES, S., M. DAUTI, C. WILDE, D. MAZEL and D. A. ROWE-MAGNUS, 2007 Chromosomal toxin-antitoxin loci can diminish large-scale genome reductions in the absence of selection. *Mol. Microbiol.* **63**: 1588–1605.
- TOBES, R., and E. PAREJA, 2006 Bacterial repetitive extragenic palindromic sequences are DNA targets for insertion sequence elements. *BMC Genomics* **7**: 62.
- TSILIBARIS, V., G. MAENHAUT-MICHEL, N. MINE and L. VAN MELDEREN, 2007 What is the benefit to *Escherichia coli* of having multiple toxin-antitoxin systems in its genome? *J. Bacteriol.* **189**: 6101–6108.
- WILBAUX, M., N. MINE, A. M. GUEROUT, D. MAZEL and L. VAN MELDEREN, 2007 Functional interactions between coexisting toxin-antitoxin systems of the *ccd* family in *Escherichia coli* O157:H7. *J. Bacteriol.* **189**: 2712–2719.
- WILDE, C., F. ESCARTIN, S. KOKEGUCHI, P. LATOUR-LAMBERT, A. LECTARD *et al.*, 2003 Transposases are responsible for the target specificity of IS1397 and ISKpn1 for two different types of palindromic units (PUs). *Nucleic Acids Res.* **31**: 4345–4353.
- YANG, Z., 1997 PAML: a program package for phylogenetic analysis by maximum likelihood. *Comput. Appl. Biosci.* **13**: 555–556.
- YANG, Z., 2007 PAML 4: phylogenetic analysis by maximum likelihood. *Mol. Biol. Evol.* **24**: 1586–1591.
- YARMOLINSKY, M. B., 1995 Programmed cell death in bacterial populations. *Science* **267**: 836–837.

Communicating editor: J. LAWRENCE